The peptide accelerated healing despite the metabolic impairments of diabetes, outperforming becaplermin (an FDA-approved diabetic wound treatment) in several parameters
GLP-1s for all isnt cost-effective, Dr
Okun The New England Journal of Medicines recent publication of a randomized study of a GLP-1 agonist originally designed for diabetes, but applied to Parkinson's disease, has led to a flurry of excitement and to a mountain of questions
Wu W, Wang P, Cheng JX, Xu XM
Maintaining optimal levels of glutathione appears to be important for supporting cognitive function, especially as we age.* The normal process of aging is associated with a decrease in glutathione regulation, which can result in increased oxidative activity.* Less than optimum levels of glutathione are observed in individuals experiencing a decline in cognitive function.* Conversely, individuals living over 100 years tend to have higher glutathione reductase activity.* A common mistaken belief is that glutathione is not well absorbed when its taken orally, but significant data confirms it is efficiently absorbed across the intestinal epithelium by a specific uptake system.* Glutathione-SR from Thorne Research represents an important breakthrough in glutathione supplementation
My co-authors and I were fascinated by the large and impressive randomized controlled trial impacts of GLP-1s
